We are currently performing scheduled maintenance to improve our services. Temporary disruptions may occur. For assistance, please reach out to our support team.
Last updated at 23 hours ago
Director
DIN: 08134151
Aman Chirania is currently associated with 2 companies in various capacities such as Director, Individual Promoter and Designated Partner. They serve as a Director at GROMAX THERAPEUTICS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08134151.Aman Chirania is currently involved in 3 different roles. Their most recent position is with PAS RESTRO LLP as a Designated Partner. The first company Aman Chirania was appointed to as a director was GROMAX THERAPEUTICS PRIVATE LIMITED. Aman Chirania is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Aman Chirania is currently associated with 2 companies in various capacities such as Director, Individual Promoter and Designated Partner. They serve as a Director at GROMAX THERAPEUTICS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 08134151.Aman Chirania is currently involved in 3 different roles. Their most recent position is with PAS RESTRO LLP as a Designated Partner. The first company Aman Chirania was appointed to as a director was GROMAX THERAPEUTICS PRIVATE LIMITED. Aman Chirania is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
3
Male
India
Gain instant access to verified contact details.
Current Companies (1)
Current LLPs (1)
Past Companies (0)
1y 4m 8 Months Interval
Company Name | Designation | Date of Appointment |
---|---|---|
GROMAX THERAPEUTICS PRIVATE LIMITED | Director | 15-May-2018 |
GROMAX THERAPEUTICS PRIVATE LIMITED | Individual Promoter | 15-May-2018 |